Roche to buy gene therapy specialist Spark in US$4.3 billion deal

Roche to buy gene therapy specialist Spark in US$4.3 billion deal

Roche on Monday said it will buy Spark Therapeutics in a transaction valued at US$4.3 billion as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy with rivals like Novartis.

FILE PHOTO - Logo of Swiss drugmaker Roche is seen at its headquarters in Basel
FILE PHOTO - The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann

ZURICH: Roche on Monday said it will buy Spark Therapeutics in a transaction valued at US$4.3 billion as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy with rivals like Novartis.

Roche will acquire U.S.-based Spark for US$114.50 per share, a premium of about 122 percent to Spark's closing price on Feb. 22, the Swiss company said in a statement.

(Reporting by John Miller; editing by Thomas Seythal)

Source: Reuters

Bookmark